title: Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome.
abstract: OBJECTIVE
  To observe and compare the clinical curative effect of the plasma exchange (PE) and intravenous immunoglobulin (IVIg) for Guillian-Barre Syndrome (GBS).
  
  
  METHODS
  Overall, 64 adult patients with GBS for PE and IVIg treatment, respectively, and nerve function were observed pre-treatment and at 1 week/2 weeks after completion of treatment; the blood immunoglobulin, complement, fibrinogen (Fib) and monocyte percentage (MON%) were detected simultaneously.
  
  
  RESULTS
  After PE treatment, nerve function defect appeared to improve better than the IVIg group and clinical effect was better than the IVIg group. Treatment effective rates of the two groups after 2 weeks, respectively, are 96 and 79%. PE and IVIg can significantly reduce the GBS patients' blood immunoglobulin IgG, IgA, IgM, C3 and C4, but these were significantly lower in the PE group than in the IVIg group. Fib and MON% were significantly lower in the PE group than in the IVIg group.
  
  
  CONCLUSIONS
  Both PE and IVIg have a high response as therapy and are reasonable therapeutic options for GBS. However, PE treatment has a more significantly curative effect, as it can effectively improve symptoms and be helpful in the early rehabilitation of patients.
authors.affiliation: Department of Blood Transfusion, The Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, 710077, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Ye
authors.affiliation: Department of Blood Transfusion, The Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, 710077, China.
authors.forename: S-L
authors.initials: SL
authors.lastname: Li
authors.affiliation: Department of Neurology, The Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi, 710077, China.
authors.forename: Y-J
authors.initials: YJ
authors.lastname: Li
mesh_terms: D000328:Adult; D003165:Complement System Proteins / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005500:Follow-Up Studies; D020275:Guillain-Barre Syndrome / Q000628:therapy*; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007165:Immunosuppression Therapy / Q000379:methods; D007958:Leukocyte Count; D008297:Male; D009000:Monocytes; D009460:Neurologic Examination; D010951:Plasma Exchange; D055815:Young Adult
chemical_list: D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D005340:Fibrinogen; D003165:Complement System Proteins
keywords: Guillian-Barre syndrome; intravenous immuno-globulin; plasma exchange